The Federal Government says consignments of Lenacapavir, a breakthrough HIV prevention drug, are expected to arrive in Nigeria in March 2026.
In a statement on Monday, the National Agency for the Control of AIDS (NACA) said preparations are in advanced stages for the introduction and rollout of Lenacapavir (LEN) as pre-exposure prophylaxis (PrEP). The move, it noted, is part of efforts to accelerate progress toward HIV epidemic control in the country.
Lenacapavir is a long-acting injectable PrEP option administered just twice a year. Clinical trials have shown it significantly reduces the risk of HIV infection, offering near-total protection when properly used.
“Commodities are expected in country in March 2026,” the agency stated, adding that coordinated measures are underway to ensure a structured and quality-assured rollout in priority states.
NACA said Nigeria is on course for a phased introduction of LEN PrEP, supported by regulatory clearance, health system preparedness, trained personnel and community engagement strategies.
Among key milestones already achieved is regulatory approval by the National Agency for Food and Drug Administration and Control (NAFDAC).
The agency also disclosed that landscape and readiness assessments have been completed in 10 states — Akwa Ibom, Anambra, Benue, Cross River, Ebonyi, the Federal Capital Territory, Gombe, Kano, Kwara and Lagos — to evaluate service delivery capacity and identify implementation gaps.
In preparation for the rollout, NACA conducted a national training of trainers in Abuja, followed by step-down training for healthcare workers in selected states. Information, education and communication materials have also been developed to support awareness campaigns and generate demand ahead of the drug’s introduction.
The government says the initiative underscores its commitment to strengthening HIV prevention and expanding access to innovative treatment options nationwide.